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We describe a patient with acute leukemia of ambiguous lineage who had trisomy 4 as the sole
cytogenetic abnormality. Clinical, pathological, immunophenotypic and molecular features are presented
and compared with the previous 4 published cases. Over expression of c-kit, which is localized to
chromosome 4, was documented on the leukemic blasts. Prognosis seems to be poor. Treatment with
acute lymphoblastic leukemia like regimens seems to be superior compared to acute myeloid leukemia
like regimens and allogeneic stem cell transplant is recommended after achieving remission.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The 2008 World health organization (WHO) deﬁnes acute leuke-
mias with ambiguous lineage (ALAL) as those leukemias which show
no clear differentiation towards either myeloid or lymphoid lineage. It
includes acute undifferentiated leukemias which express no speciﬁc
markers for both lineage and mixed phenotypic acute leukemia
(MPAL) which express antigens of both myeloid and lymphoid lineage
to such a degree that it is impossible to assign a speciﬁc lineage [1].
Cytogenetic abnormalities strongly inﬂuence prognosis in cases
of acute leukemias. Amongst patients with MPAL, the most
commonly reported cytogenetic abnormalities are t (9;22) affect-
ing the Abelson (ABL) oncogene, chromosome 11 abnormalities
affecting the mixed leukemia lineage (MLL) gene and a complex
karyotype with 3 or more abnormalities [2,3].
Trisomy 4 as the sole cytogenetic abnormality in acute leuke-
mia is quite unusual. It has a reported prevalence of 0.0655% in
acute myeloid leukemia (AML) and is even less common in acute
lymphoblastic leukemia (ALL) [4,5].
We describe a case of mixed phenotypic acute leukemia with
trisomy 4 as the sole cytogenetic abnormality. A literature search
describing other 4 published cases is also presented.
2. Case report
A 50 year old hispanic female was admitted to our hospital
with a 1 week history of headaches, palpitations and fatigue. Her
prior medical history was unremarkable. She worked as a waitress
and had no known environmental exposure to carcinogenic
agents. On the day of admission, she had a brief syncopal episode.
On examination she had a temperature of 38.2 1C. Conjunctival
and mucosal pallor was noted. Multiple 1–2 cm freely mobile
lymph nodes were palpable in the cervical, sub mental and sub
occipital regions. Spleen tip was palpable. A petechial rash was
noted extending from the feet to the thighs. Complete blood
counts revealed a white cell count of 403,000/mr, hemoglobin of
3.2 gm/dl and a platelet count of 6000/ml. Peripheral blood smear
showed more than 50% of the nucleated cells to be leukemic blasts
with high nuclear/cytoplasmic ratio, and minimally indented
nuclei. Majority of circulating neutrophils showed dysplastic
features in the form of hypo-lobate nuclei and hypo-granular
cytoplasm (Fig. 1a). Platelets were markedly decreased in number.
Kidney and liver functions were normal. Cerebrospinal ﬂuid
analysis was not consistent with leukemic meningitis.
Bone marrow showed 100% cellularity of which 95% was
inﬁltration by blasts. The blasts had a high nuclear/cytoplasmic
ratio and indented nuclei. Auer rods were not present. Strong c-kit
expression was noted by immunohisotchemistry (1b). Flow cyto-
metry showed the blasts to express CD117, cytoplasmic CD3, CD2,
CD7 and myeloperoxidase (MPO) (Fig. 2a–f).
Fluorescent in situ hybridization (FISH) studies did not show
bcr/abl (breakpoint cluster region/Abelsen), PML/RARA (promye-
locytic leukemia/retinoic acid receptor alpha), CBFB/MYH11 (core
binding factorβ/myosin heavy chain11), AML1/ETO (acute myeloid
leukemia 1/eight-twenty one), ETV6/RUNX1 (ETS variant 6/Runt
related transcription factor 1) translocation or MLL (mixed lineage
leukemia) gene rearrangement.
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Polymerase chain reaction (PCR) studies did not show T cell
receptor β gene arrangement, CEBPA (CCAAT enhancer binding
protein alpha) mutation or FLT3 (fms like tyrosine kinase 3)
internal tandem duplication or tyrosine kinase domain mutation.
No activating mutations in the c-kit gene were identiﬁed. Cytoge-
netic studies showed trisomy 4 in all 20 metaphases.
Patient was diagnosed with mixed phenotypic (t/myeloid) acute
leukemia. She underwent emergent leukapheresis and was then
started on hyper-fractionated cyclophosphamide, vincristine, doxor-
ubicin and dexamethasone (hyper CVAD) regimen. She also received
intrathecal injections of methotrexate and cytarabine for CNS
prophylaxis. A repeat bone marrow was obtained on day 27, when
she had recovered her peripheral blood counts and was no longer
requiring transfusion support. This showed complete morphologic
and cytogenetic response which has been maintained after 7 addi-
tional cycles of alternating hyper CVAD, methotrexate and high dose
Fig. 1. Peripheral smear showing hypogranular, hypolobate neutrobils and leukemic blasts (1a) and bone marrow aspirate cell block showing strong expression of c-kit on
leukemic blasts (1b).
Fig. 2. Flow cytometry plots. Leukemic blasts express CD45 and show low side scattter (a). They express CD34 and CD117 (b). They also express CD7, MPO, cytoplasmic CD3
and TDT (c–f).
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cytarabine. No matched related stem cell donors were found and she
is being evaluated for a matched unrelated donor transplant.
3. Discussion
The 2008 WHO criteria for MPAL relies on immunophenotypic
demonstration of antigens of more than one lineage (myeloid, b
lymphocytic or t lymphocytic), exclusion of AML cases with recurrent
cytogenetic abnormalities and exclusion of AML with myelodysplasia
(MDS) related changes [1]. The expression of cytoplasmic CD3 and
myeloperoxidase on the blasts of our patient support the diagnosis of
MPAL. Recurrent cytogenetic abnormalities commonly seen in acute
myeloid leukemia were excluded. The presence of signiﬁcant number
of hypo-granular and hypolobate neutrophils in our patients blood
smear initially led to a suspicion of myelodysplastic syndrome related
acute leukemia. However, we did not identify any signiﬁcant dysplastic
features in her erythroid or megakaryocytic series and there was no
history of an antecedent hematological disease. The 2008 WHO
criteria for AML with MDS related changes requires the demonstration
of dysplastic features in 2 or more cells of myeloid series. This
requirement was not met and our patient was diagnosed with MPAL.
Cytogenetic ﬁndings are important determinants of prognosis
in cases of acute leukemia and in some instances deﬁne speciﬁc
subtypes of acute leukemias with distinct biology and clinical
features. We performed a literature search and identiﬁed 4 pre-
viously published reports of trisomy 4 associated biphenotypic
acute leukemia. These are presented in Table 1.
Of note, cases reported by Britton et al. and Keung et al. rely on
the demonstration of CD7 and TDT along with myeloid markers to
classify the blasts as “biphenotypic” [8,9]. Expression of CD3 is not
reported by the authors and these cases would not meet the
current 2008 WHO criteria for MPAL.
Age of these patients vary from 5 to 50 years with a median age
of 24. There were 2 males and 3 females. Among these 5 reported
cases, 2 are of hispanic decent (40%) and this association should be
explored further in larger series. Four cases expressed t/myeloid
antigens and one expressed b/myeloid markers. Of the three cases
with t/myeloid MPAL who underwent molecular studies for t-cell
receptor (TCR) gene rearrangement, none showed a clonaly rear-
ranged TCR. CBC showed a median white cell count of 40,400/ml
(range 5500–403,000/ml), hemoglobin of 8.9 g/dl (range 3.2–9.6 g/dl)
and platelet count of 27,000/ml (range 6000–91,000/ml). Median blast
count was 80% (range 54–95%). Blast morphology was most com-
monly reported as resembling FAB L2.
Presence of trisomy raises the possibility of added gene dose
contributing to the leukemogenic process. The oncogene, c-kit, is
localized to chromosome 4. Leukemic blasts of our patient strongly
expressed c-kit. c-Kit expression was not studied in the other
4 reported cases of MPAL. Increased expression of c-kit in patients
with acute myeloid leukemia harboring trisomy 4 has been docu-
mented in the past [10]. Activating c-kit mutations were not
detected in our patient and as c-kit expression is a common ﬁnding
in acute myeloid leukemia's irrespective of cytogenetic features, the
role of c-kit in these leukemias remain speculative [11].
One of the reported cases of trisomy 4 associated MPAL
identiﬁed prior pesticide exposure of the patient before develop-
ment of acute leukemia [7]. The presence of pseudo Pelger-Huet
cells in our patient also raises the possibility of a prior environ-
mental exposure contributing to the dysplastic changes. Of note,
case reports of AML with trisomy 4 have also previously reported
environmental exposure as a possible risk factor [12].
Three patients received an AML like induction based on
cytarabine and anthracycline. Of these, two failed to achieve a
remission and the third relapsed in 10 months. Two patients
(including this case) received an ALL like regimen. Both achieved a
complete remission. This is consistent with prior reports suggest-
ing superior responses to an ALL like regimen in MPAL [2].
4. Conclusions
MPAL with trisomy 4 is a rare malignancy with heterogenous
clinical and immunophenotypic features. Further studies need to
clarify the potential role of environmental toxin exposures and
role of c-kit oncogene in the pathogenesis of this disease. In
addition, future case reports need to specify the racial background
of the patients to see if there is a hispanic predisposition.
Prognosis is poor however outcomes seem better when ALL like
treatment protocols are followed.
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Table 1
Reference Age (years) Sex Race Country Immuno-phenotype CD117 Induction therapy Complete response (duration)
6 22 Female NR Saudi Arabia t-Myeloid NR Cytarabine, idarubicin 
7 44 Male NR Italy b-Myeloid NR Vincristine/daunorubicin/endoxan þ (50 days)
8 5 Female NR Australia t-Myeloid NR Vincristine/daunorubicin/cytarabine 
9 24 Male hispanic US t-Myeloid NR Cytarabine/daunorubicin þ (10 months)
Present 50 Female hispanic US t-Myeloid þ Hyper CVAD þ (6 months)
NR: not reported; : not achieved; þ: achieved, and hyper CVAD: hyper-fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone.
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